On May 6, 2026, Kristen Fortney, Ph.D., the Company's Chief Executive Officer, President, and a member of its Board of Directors, adopted a Rule 10b5-1 trading plan. Dr. Fortney's Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and provides for the potential exercise and sale of up to 180,000 shares of the Company's common stock subject to stock options held by Dr. Fortney at a minimum price of $20.00 per share until August 15, 2027. Dr. Fortney's Rule 10b5-1 trading plan also provides for the potential sale of up to 180,000 shares of the Company's common stock held by Dr. Fortney at minimum prices ranging from $30.00 to $44.00 per share until August 15, 2027.

On April 29, 2026, Eric Morgen, M.D., the Company's Chief Operating Officer and a member of its Board of Directors, adopted a Rule 10b5-1 trading plan. Dr. Morgen's Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and provides for the potential exercise and sale of up to 355,813 shares of the Company's common stock subject to stock options held by Dr. Morgen at minimum prices ranging from $18.00 to $60.00 per share until December 31, 2027. Dr. Morgen's Rule 10b5-1 trading plan also provides for the potential sale of up to 33,612 shares of the Company's common stock held by Dr. Morgen at a minimum price of $18.00 per share until December 31, 2027.

On April 24, 2026, Ling Chen, M.D., the spouse of Eric Morgen, M.D., the Company's Chief Operating Officer and a member of its Board of Directors, adopted a Rule 10b5-1 trading plan, which Dr. Chen subsequently modified on April 28, 2026. Because Dr. Morgen is deemed to beneficially own the shares held by Ling Chen, the plan is reported as Dr. Morgen's. Dr. Chen's Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and provides for the potential exercise and sale

of up to 29,715 shares of the Company's common stock subject to stock options held by Dr. Chen at minimum prices ranging from $18.00 to $40.00 per share until December 31, 2027.

On April 23, 2026, Dov Goldstein, M.D., the Company's Chief Financial Officer, adopted a Rule 10b5-1 trading plan, which Dr. Goldstein subsequently modified on April 27, 2026. Dr. Goldstein's Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and provides for the potential exercise and sale of up to 20,000 shares of the Company's common stock subject to a stock option held by Dr. Goldstein at minimum prices ranging from $19.00 to $22.00 per share until October 29, 2027.

On April 30, 2026, Paul Rubin, M.D., the Company's Chief Medical Officer, adopted a Rule 10b5-1 trading plan. Dr. Rubin's Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and provides for the potential exercise and sale of up to 96,000 shares of the Company's common stock subject to a stock option held by Dr. Rubin at a minimum price of $14.50 per share until October 29, 2027.

On April 27, 2026, Rekha Hemrajani, a member of the Company's Board of Directors, adopted a Rule 10b5-1 trading plan. Ms. Hemrajani's Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and provides for the potential exercise and sale of up to 22,000 shares of the Company's common stock subject to stock options held by Ms. Hemrajani at minimum prices ranging from $27.00 to $30.00 per share until October 29, 2027. Ms. Hemrajani's Rule 10b5-1 trading plan also provides for the potential sale of up to 3,000 shares of the Company's common stock held by Ms. Hemrajani at a minimum price of $33.00 per share until October 29, 2027.

The Rule 10b5-1 trading plans listed above each included a representation from the director or officer to the broker administering the plan that they were not in possession of any material nonpublic information regarding the Company or the securities subject to the plan. A similar representation was made to the Company by each director or officer in a certification provided to us in connection with the adoption of the plan under the Company’s insider trading policy. Those representations were made as of the date of adoption of each Rule 10b5-1 trading plan or certification, as applicable, and speak only as of those dates. In making those representations, there is no assurance with respect to any material nonpublic information of which the director or officer was unaware, or with respect to any material nonpublic information acquired by the director or officer or the Company after the applicable date of the representation.